The Tyrosine Protein Kinase JAK3 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase JAK3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase JAK3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Immunology, Dermatology, Gastrointestinal, and Musculoskeletal Disorders which include the indications Rheumatoid Arthritis, Psoriasis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Ulcerative Colitis, Inflammatory Bowel Disease, Arthritis, and Cachexia. It also reviews key players involved in Tyrosine Protein Kinase JAK3 targeted therapeutics development with respective active and dormant or discontinued products.

The Tyrosine Protein Kinase JAK3 pipeline targets constitutes close to 30 molecules. Out of which, approximately 30 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 3, 4, 7, 12, and 2 respectively.

Tyrosine Protein Kinase JAK3 overview

Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

For a complete picture of Tyrosine Protein Kinase JAK3’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.